

Special Issue

Molecular Mechanisms in Transplant-Related Diseases: After Solid Organ/Bone Marrow Transplantation

Message from the Guest Editor

Solid organ/bone marrow transplantation is considered the optimal therapeutic choice for end-stage organ and hematological diseases. It can significantly increase patient survival and improve quality of life. However, transplantation is not a panacea. Despite significant surgical and immune pharmacological advancements, transplant recipients still do not acquire the life expectancy of their age-matched healthy peers. The molecular mechanisms in transplant-related diseases remain unclear, and understanding of the molecular mechanisms of this area is still a major challenge at present. Therefore, this Special Issue provides us with an opportunity to deeply discuss the molecular mechanisms in transplant-related diseases. In this Special Issue, we welcome submissions of original research (basic and clinical research), case reports, and review articles focusing on, but not limited to, molecular mechanisms in transplant-related diseases after solid organ and bone marrow transplantation.

Guest Editor

Dr. Yuanyuan Zhao

Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Education and Ministry of Health, Wuhan 430030, China

Deadline for manuscript submissions

closed (20 January 2024)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/177148

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))